Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Femke van den Ham

Femke van den Ham

Research Technician

Neuroblastoma immunology and immunotherapy

Project description:

The aim of this project is to 1) identify novel targets for immunotherapeutic interventions in neuroblastoma, 2) develop and investigate innovative (combinations of) immunotherapeutic interventions for clinical applicability, with the ultimate goal of introducing novel treatment options for neuroblastoma.

We will investigate the immune environment of neuroblastoma, and possibly other tumours, starting with single cell RNA sequencing and isolation of tumour-infiltrating immune cells to identify novel targets for immunotherapy. Target identification will be aimed at both undermining tumour immune evasion and increasing the anti-tumour effectivity of immune cells. After target validation, different innovative strategies and combinations of immunotherapeutic interventions will be tested; first in vitro on tumour cell lines and organoids, and later in vivo in murine models. Ultimately, effective interventions will be introduced into the clinical trial phase

Telephone:

E-mail: f.vandenham-2@prinsesmaximacentrum.nl

Phone 088 97 27 678


The aim of this project is to 1) identify novel targets for immunotherapeutic interventions in neuroblastoma, 2) develop and investigate innovative (combinations of) immunotherapeutic interventions for clinical applicability, with the ultimate goal of introducing novel treatment options for neuroblastoma.

We will investigate the immune environment of neuroblastoma, and possibly other tumours, starting with single cell RNA sequencing and isolation of tumour-infiltrating immune cells to identify novel targets for immunotherapy. Target identification will be aimed at both undermining tumour immune evasion and increasing the anti-tumour effectivity of immune cells. After target validation, different innovative strategies and combinations of immunotherapeutic interventions will be tested; first in vitro on tumour cell lines and organoids, and later in vivo in murine models. Ultimately, effective interventions will be introduced into the clinical trial phase.